ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

TACI-Ig as a Desensitization Agent in a Rat Model of Antibody Mediated Rejection

N. Wilson,1 B. Verhoven,2 B. Boldt,2 N. Bath,2 X. Ding,1 R. Redfield III.2

1Medicine/Nephrology, University of Wisconsin, Madison, WI
2Surgery/Transplant, University of Wisconsin, Madison, WI.

Meeting: 2018 American Transplant Congress

Abstract number: D13

Keywords: Alloantigens, B cells, Kidney transplantation, Sensitization

Session Information

Date: Tuesday, June 5, 2018

Session Name: Poster Session D: B-cell / Antibody

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Related Abstracts
  • APRIL/BLyS Blockade Improves Depletion of Antibody Secreting B Cells Compared to BLyS Blockade Alone in Sensitized Murine Kidney Transplant Model
  • APRIL/BLyS Inhibition Reduces Donor Specific Antibody in Sensitized Mice.

We examined the effect of APRIL/BLyS blockade on B cell lineages & donor specific antibody (DSA) in preclinical rodent model as a novel desensitization strategy. Limited success in desensitization protocols require new ideas to transplant patients with high cPRA. APRIL and BLyS are critical survival factors for B lymphocytes and plasma cells, the main source of alloantibody production.

Lewis rats were sensitized by i.v. injection of 0.5 ml heparinized Brown Norway (BN) blood. 21 days after sensitization, rats were treated with 250 mg of TACI-Ig administered 3x/week for 21 days. B cell subset analysis by flow cytometry and flow cross match (FXM) were performed to assess the effect of APRIL/BLyS inhibition. The three groups are baseline, transfusion (Tn) and transfusion with 21d TACI Ig (Tn + TACI Ig).

In animals that were sensitized and treated with TACI-Ig, we observed a significant reduction in Marginal Zone B cells in the spleen (p<0.01) , bone marrow (BM, p<0.002), lymph nodes (LN, p<0.003) and PBMC (p<0.003), as well as significant reductions in Transitional cells in BM (p<0.002), LN (p<0.003) and PBMC (p<0.003). We also observed a significant reduction in Plasma Cells in both spleen (p<0.005) and BM (p<0.04). All sensitized animals had significantly elevated DSA for all isotypes. However, the only isotype that was reduced by TACI-Ig treatment was IgG2a (p<0.004).

In Lewis rats, TACI Ig was able to reduce many B cell subsets, including plasma cells. Only IgG2a isotype DSA were reduced by the TACI Ig treatment. The TACI used in the construct for the drug was optimized for mouse sequence, not rat sequence. Even though the mouse and rat proteins are related, evidently there are sufficient differences to result in reduced effect on DSA desensitization.

CITATION INFORMATION: Wilson N., Verhoven B., Boldt B., Bath N., Ding X., Redfield III R. TACI-Ig as a Desensitization Agent in a Rat Model of Antibody Mediated Rejection Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Wilson N, Verhoven B, Boldt B, Bath N, Ding X, III RRedfield. TACI-Ig as a Desensitization Agent in a Rat Model of Antibody Mediated Rejection [abstract]. https://atcmeetingabstracts.com/abstract/taci-ig-as-a-desensitization-agent-in-a-rat-model-of-antibody-mediated-rejection/. Accessed March 8, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Search
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.